PROCEPT BioRobotics (PRCT) Q1 2026 earnings review
Strategic Reset Shows Early Promise Amid Procedure Growth Normalization
PROCEPT's painful Q4 decision to eliminate end-of-quarter bulk discounts is already bearing fruit. The business is stabilizing: revenue grew 20% YoY to $83.1 million (beating Q1 guidance), handpiece average selling prices (ASP) hit the $3,500 target, and gross margin rebounded to 65%. Most importantly, the handpiece-to-procedure ratio normalized to ~95%, indicating that the channel destocking is largely complete. However, underlying US procedure growth decelerated sharply to 30% YoY (flat sequentially at 12,200). With full-year procedure growth guidance maintained at 39-48%, management is betting heavily on a massive second-half acceleration driven by their newly realigned commercial team.
🐂 Bull Case
The Q4 transition shock is over. Handpiece ASPs successfully reached the $3,500 target (+5% sequentially), proving that hospital demand for Aquablation remains inelastic despite the removal of bulk purchasing incentives.
The company sold 49 US Hydros systems at an impressive ASP of ~$485,000 (accelerating from ~$425,000 in late 2025). The clearance of the FirstAssist AI software makes the capital pitch even stronger.
🐻 Bear Case
With Q1 procedures flat sequentially, hitting the reiterated 39-48% full-year procedure growth guidance requires a massive acceleration in the back half of the year. Any prolonged disruption from the commercial sales force reorganization will cause a guidance miss.
Despite higher ASPs and improved gross margins, Adjusted EBITDA loss worsened to $18.1 million. The company is burning cash faster YoY to fund commercial expansion and clinical trials.
⚖️ Verdict: ⚪
Neutral. The quick recovery in ASPs and gross margin is highly encouraging, proving management's Q4 narrative was accurate. However, flat sequential procedure growth creates a steep hill to climb for the rest of the year, demanding flawless commercial execution.
Key Themes
Pricing Discipline Drives Margin Recovery
The painful Q4 reset—ending historical bulk discounts—worked exactly as management promised. Handpiece ASP increased 5% sequentially to ~$3,500, which management had set as their 2026 target. This structural pricing improvement single-handedly drove the Reversing trend in gross margin, bringing it back to 65% (from 61% in Q4) despite ongoing tariff headwinds.
Inventory Destocking is Complete
For years, handpiece sales outpaced actual procedures by 108%-116%, creating a channel inventory overhang. In Q4, this ratio crashed to ~77% as customers depleted stock. In Q1 2026, the ratio normalized to ~95%. This Reversing trend signals the destocking phase is largely over; moving forward, reported handpiece revenue will reliably reflect actual hospital utilization.
FirstAssist AI Clearance Elevates Hydros
PROCEPT received FDA clearance for its second-generation FirstAssist AI software. This AI-powered image guidance enables more precise identification of prostate anatomy. This technology innovation is directly translating to pricing power: the ASP for the 49 new Hydros systems sold in Q1 was ~$485,000, a massive step up from the ~$425,000 ASP seen in Q4 2025.
Procedure Growth Deceleration Contradicts Reorg Optimism
Management stated the commercial realignment is having an 'early impact,' yet US procedure volume was flat sequentially at ~12,200. YoY growth Decelerated sharply from 69% in Q4 to 30% in Q1. While Q1 is historically slower, this magnitude of deceleration casts doubt on the company's ability to hit its aggressive 39-48% full-year procedure growth targets without a flawless H2 execution.
Persistent Tariff Headwinds
Macro pressures remain visible. Management noted that Q1 gross margin gains were partially offset by increased tariff expenses compared to the prior year. In prior quarters, the company flagged up to $5M-$6M in 2026 tariff exposure related to Chinese components (like ultrasound units). This limits further gross margin expansion potential.
Commercial Expansion Extends Cash Burn
Operating expenses Accelerating 21% YoY to $86.6M resulted in a wider Net Loss ($31.6M vs $24.7M YoY) and worse Adjusted EBITDA ($18.1M loss vs $15.8M loss). While management cites necessary investments in the commercial team and the WATER IV Prostate Cancer trial, the lack of operating leverage on 20% revenue growth will test investor patience.
Other KPIs
Accelerating slightly. International revenue grew 25% YoY, outpacing US revenue growth (19%). This builds on the foundation laid in 2025, where focus markets like the UK drove expansion. It now represents over 13% of total company revenue.
Decelerating. Total cash balances dropped from $286.5 million at the end of 2025. With a Q1 cash burn of roughly $37.5 million, the company remains well-capitalized for the near term, but the aggressive commercial and clinical spending limits any margin for error.
Guidance
Stable. The company reiterated its full-year guidance, which implies an Accelerating YoY growth rate of 27% to 33% (up from 20% in Q1). Achieving this requires significant top-line acceleration in the second half of the year as the new commercial launch team structure matures.
Stable. Maintained guidance despite a softer 30% growth rate in Q1. Management clearly anticipates a back-half loaded year where patient activation initiatives and normalized hospital rep territories trigger an exponential jump in utilization.
Stable. With an $18.1M loss already booked in Q1, hitting even the high end ($30M loss) of this guidance requires aggressive sequential margin improvement and operating leverage through the rest of the year. Positive EBITDA is targeted for Q4 2026.
Key Questions
Procedure Acceleration Path
US procedure growth decelerated to 30% in Q1, and volume was flat sequentially. What specific leading indicators—such as time-to-first-case from the new dedicated launch teams—give you confidence that growth will re-accelerate to meet the 39-48% full-year target?
Hydros ASP Sustainability
The $485,000 ASP for the Hydros system is exceptionally strong. How much of this premium is driven by the new FirstAssist AI software clearance, and do you view this ASP as sustainable for the remainder of the year?
Commercial Reorganization Disruption
You mentioned the commercial realignment created 'some near-term disruption.' Can you quantify this impact? Are you seeing higher rep attrition in specific geographies, and how long does it take for a newly placed territory manager to reach legacy productivity levels?
Path to Q4 Profitability
With an $18.1 million Adjusted EBITDA loss in Q1, achieving the full-year target implies a dramatic turn toward profitability. Beyond volume leverage, are there specific OpEx cuts or R&D roll-offs (e.g., WATER IV enrollment milestones) expected in H2 to facilitate the Q4 breakeven target?